nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—FGFR2—uterine cancer	0.438	1	CbGaD
Regorafenib—UGT1A1—Etoposide—uterine cancer	0.0291	0.106	CbGbCtD
Regorafenib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0288	0.105	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—uterine cancer	0.0284	0.103	CbGbCtD
Regorafenib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0201	0.073	CbGbCtD
Regorafenib—ABCG2—Carboplatin—uterine cancer	0.0191	0.0694	CbGbCtD
Regorafenib—CYP2C8—Progesterone—uterine cancer	0.0191	0.0693	CbGbCtD
Regorafenib—ABCG2—Etoposide—uterine cancer	0.016	0.0582	CbGbCtD
Regorafenib—CYP2C19—Progesterone—uterine cancer	0.016	0.0582	CbGbCtD
Regorafenib—CYP2C9—Progesterone—uterine cancer	0.0133	0.0484	CbGbCtD
Regorafenib—ABCB1—Progesterone—uterine cancer	0.0129	0.0469	CbGbCtD
Regorafenib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0117	0.0424	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—uterine cancer	0.0109	0.0397	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—uterine cancer	0.0102	0.0372	CbGbCtD
Regorafenib—CYP2C8—Etoposide—uterine cancer	0.00854	0.031	CbGbCtD
Regorafenib—CYP3A4—Progesterone—uterine cancer	0.00774	0.0281	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—uterine cancer	0.00769	0.0279	CbGbCtD
Regorafenib—ABCB1—Etoposide—uterine cancer	0.00578	0.021	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—uterine cancer	0.00394	0.0143	CbGbCtD
Regorafenib—CYP3A4—Etoposide—uterine cancer	0.00346	0.0126	CbGbCtD
Regorafenib—CYP3A4—Doxorubicin—uterine cancer	0.00236	0.00858	CbGbCtD
Regorafenib—TEK—artery—uterine cancer	0.00139	0.0165	CbGeAlD
Regorafenib—DDR2—myometrium—uterine cancer	0.00137	0.0162	CbGeAlD
Regorafenib—NTRK1—decidua—uterine cancer	0.00137	0.0162	CbGeAlD
Regorafenib—FLT1—artery—uterine cancer	0.00135	0.0159	CbGeAlD
Regorafenib—FGFR2—exocrine gland—uterine cancer	0.00127	0.015	CbGeAlD
Regorafenib—KDR—artery—uterine cancer	0.00114	0.0135	CbGeAlD
Regorafenib—FRK—renal system—uterine cancer	0.00111	0.0132	CbGeAlD
Regorafenib—DDR2—uterine cervix—uterine cancer	0.00107	0.0126	CbGeAlD
Regorafenib—DDR2—smooth muscle tissue—uterine cancer	0.00104	0.0123	CbGeAlD
Regorafenib—DDR2—decidua—uterine cancer	0.00102	0.012	CbGeAlD
Regorafenib—DDR2—endometrium—uterine cancer	0.000966	0.0114	CbGeAlD
Regorafenib—DDR2—mammalian vulva—uterine cancer	0.000934	0.0111	CbGeAlD
Regorafenib—EPHX2—myometrium—uterine cancer	0.000927	0.011	CbGeAlD
Regorafenib—FRK—female reproductive system—uterine cancer	0.000892	0.0106	CbGeAlD
Regorafenib—DDR2—uterus—uterine cancer	0.00089	0.0105	CbGeAlD
Regorafenib—KIT—exocrine gland—uterine cancer	0.000878	0.0104	CbGeAlD
Regorafenib—FGFR1—myometrium—uterine cancer	0.000825	0.00976	CbGeAlD
Regorafenib—DDR2—female reproductive system—uterine cancer	0.0008	0.00947	CbGeAlD
Regorafenib—MAPK11—female reproductive system—uterine cancer	0.000758	0.00897	CbGeAlD
Regorafenib—DDR2—female gonad—uterine cancer	0.000728	0.00861	CbGeAlD
Regorafenib—DDR2—vagina—uterine cancer	0.000724	0.00856	CbGeAlD
Regorafenib—MAPK11—female gonad—uterine cancer	0.00069	0.00817	CbGeAlD
Regorafenib—EPHA2—myometrium—uterine cancer	0.000689	0.00815	CbGeAlD
Regorafenib—BRAF—endometrium—uterine cancer	0.000683	0.00808	CbGeAlD
Regorafenib—FLT4—epithelium—uterine cancer	0.000656	0.00776	CbGeAlD
Regorafenib—FLT1—myometrium—uterine cancer	0.00065	0.00769	CbGeAlD
Regorafenib—RAF1—myometrium—uterine cancer	0.000646	0.00765	CbGeAlD
Regorafenib—FGFR1—uterine cervix—uterine cancer	0.000642	0.00759	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—uterine cancer	0.000631	0.00747	CbGeAlD
Regorafenib—BRAF—uterus—uterine cancer	0.000629	0.00744	CbGeAlD
Regorafenib—FLT4—decidua—uterine cancer	0.00062	0.00733	CbGeAlD
Regorafenib—UGT1A9—renal system—uterine cancer	0.000617	0.0073	CbGeAlD
Regorafenib—FGFR1—decidua—uterine cancer	0.000611	0.00723	CbGeAlD
Regorafenib—EPHX2—uterus—uterine cancer	0.000601	0.00711	CbGeAlD
Regorafenib—RET—epithelium—uterine cancer	0.000579	0.00685	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—uterine cancer	0.000561	0.00664	CbGeAlD
Regorafenib—FGFR2—epithelium—uterine cancer	0.00055	0.00651	CbGeAlD
Regorafenib—KDR—myometrium—uterine cancer	0.000549	0.0065	CbGeAlD
Regorafenib—RET—decidua—uterine cancer	0.000547	0.00647	CbGeAlD
Regorafenib—FGFR2—uterine cervix—uterine cancer	0.000546	0.00646	CbGeAlD
Regorafenib—EPHA2—epithelium—uterine cancer	0.000541	0.0064	CbGeAlD
Regorafenib—RET—renal system—uterine cancer	0.000537	0.00636	CbGeAlD
Regorafenib—EPHA2—uterine cervix—uterine cancer	0.000536	0.00635	CbGeAlD
Regorafenib—FGFR1—uterus—uterine cancer	0.000535	0.00633	CbGeAlD
Regorafenib—FGFR2—smooth muscle tissue—uterine cancer	0.00053	0.00628	CbGeAlD
Regorafenib—TEK—epithelium—uterine cancer	0.000528	0.00624	CbGeAlD
Regorafenib—BRAF—female gonad—uterine cancer	0.000515	0.00609	CbGeAlD
Regorafenib—BRAF—vagina—uterine cancer	0.000511	0.00605	CbGeAlD
Regorafenib—EPHA2—decidua—uterine cancer	0.000511	0.00605	CbGeAlD
Regorafenib—FGFR2—renal system—uterine cancer	0.00051	0.00604	CbGeAlD
Regorafenib—FLT1—epithelium—uterine cancer	0.00051	0.00604	CbGeAlD
Regorafenib—TEK—smooth muscle tissue—uterine cancer	0.000508	0.00602	CbGeAlD
Regorafenib—RAF1—epithelium—uterine cancer	0.000507	0.006	CbGeAlD
Regorafenib—FLT1—uterine cervix—uterine cancer	0.000506	0.00598	CbGeAlD
Regorafenib—RAF1—uterine cervix—uterine cancer	0.000503	0.00595	CbGeAlD
Regorafenib—TEK—decidua—uterine cancer	0.000498	0.0059	CbGeAlD
Regorafenib—EPHX2—female gonad—uterine cancer	0.000492	0.00582	CbGeAlD
Regorafenib—FLT1—smooth muscle tissue—uterine cancer	0.000492	0.00582	CbGeAlD
Regorafenib—TEK—renal system—uterine cancer	0.000489	0.00579	CbGeAlD
Regorafenib—EPHX2—vagina—uterine cancer	0.000489	0.00578	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—uterine cancer	0.000489	0.00578	CbGeAlD
Regorafenib—FLT4—female reproductive system—uterine cancer	0.000487	0.00577	CbGeAlD
Regorafenib—KIT—myometrium—uterine cancer	0.000487	0.00576	CbGeAlD
Regorafenib—EPHA2—endometrium—uterine cancer	0.000485	0.00574	CbGeAlD
Regorafenib—FLT1—decidua—uterine cancer	0.000482	0.0057	CbGeAlD
Regorafenib—RAF1—decidua—uterine cancer	0.000479	0.00567	CbGeAlD
Regorafenib—PDGFRB—myometrium—uterine cancer	0.000476	0.00563	CbGeAlD
Regorafenib—FLT1—renal system—uterine cancer	0.000473	0.0056	CbGeAlD
Regorafenib—TEK—endometrium—uterine cancer	0.000473	0.0056	CbGeAlD
Regorafenib—RAF1—renal system—uterine cancer	0.00047	0.00557	CbGeAlD
Regorafenib—EPHA2—mammalian vulva—uterine cancer	0.000469	0.00555	CbGeAlD
Regorafenib—DDR2—lymph node—uterine cancer	0.000468	0.00554	CbGeAlD
Regorafenib—PDGFRA—smooth muscle tissue—uterine cancer	0.000461	0.00545	CbGeAlD
Regorafenib—FLT1—endometrium—uterine cancer	0.000457	0.00541	CbGeAlD
Regorafenib—RAF1—endometrium—uterine cancer	0.000455	0.00538	CbGeAlD
Regorafenib—FGFR2—uterus—uterine cancer	0.000455	0.00538	CbGeAlD
Regorafenib—PDGFRA—decidua—uterine cancer	0.000452	0.00534	CbGeAlD
Regorafenib—MAPK11—lymph node—uterine cancer	0.000444	0.00525	CbGeAlD
Regorafenib—FLT4—female gonad—uterine cancer	0.000443	0.00525	CbGeAlD
Regorafenib—PDGFRA—renal system—uterine cancer	0.000443	0.00525	CbGeAlD
Regorafenib—FLT1—mammalian vulva—uterine cancer	0.000442	0.00524	CbGeAlD
Regorafenib—RAF1—mammalian vulva—uterine cancer	0.00044	0.00521	CbGeAlD
Regorafenib—FGFR1—female gonad—uterine cancer	0.000437	0.00518	CbGeAlD
Regorafenib—TEK—uterus—uterine cancer	0.000436	0.00516	CbGeAlD
Regorafenib—FGFR1—vagina—uterine cancer	0.000435	0.00515	CbGeAlD
Regorafenib—KDR—epithelium—uterine cancer	0.000431	0.0051	CbGeAlD
Regorafenib—KDR—uterine cervix—uterine cancer	0.000428	0.00506	CbGeAlD
Regorafenib—ABL1—myometrium—uterine cancer	0.000424	0.00502	CbGeAlD
Regorafenib—UGT1A1—renal system—uterine cancer	0.000423	0.00501	CbGeAlD
Regorafenib—FLT1—uterus—uterine cancer	0.000422	0.00499	CbGeAlD
Regorafenib—RAF1—uterus—uterine cancer	0.000419	0.00496	CbGeAlD
Regorafenib—KDR—smooth muscle tissue—uterine cancer	0.000416	0.00492	CbGeAlD
Regorafenib—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.000412	0.00538	CcSEcCtD
Regorafenib—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.000412	0.00538	CcSEcCtD
Regorafenib—Haemoglobin—Progesterone—uterine cancer	0.000411	0.00536	CcSEcCtD
Regorafenib—FGFR2—female reproductive system—uterine cancer	0.000409	0.00484	CbGeAlD
Regorafenib—Haemorrhage—Progesterone—uterine cancer	0.000408	0.00533	CcSEcCtD
Regorafenib—KDR—decidua—uterine cancer	0.000407	0.00482	CbGeAlD
Regorafenib—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.000406	0.0053	CcSEcCtD
Regorafenib—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	0.000404	0.00527	CcSEcCtD
Regorafenib—Urinary tract disorder—Progesterone—uterine cancer	0.000403	0.00526	CcSEcCtD
Regorafenib—Stomatitis—Medroxyprogesterone Acetate—uterine cancer	0.000402	0.00524	CcSEcCtD
Regorafenib—EPHA2—female reproductive system—uterine cancer	0.000402	0.00475	CbGeAlD
Regorafenib—Connective tissue disorder—Progesterone—uterine cancer	0.000401	0.00524	CcSEcCtD
Regorafenib—Hypophosphataemia—Epirubicin—uterine cancer	0.000401	0.00524	CcSEcCtD
Regorafenib—Urethral disorder—Progesterone—uterine cancer	0.0004	0.00522	CcSEcCtD
Regorafenib—KDR—renal system—uterine cancer	0.0004	0.00473	CbGeAlD
Regorafenib—PDGFRA—uterus—uterine cancer	0.000395	0.00467	CbGeAlD
Regorafenib—TEK—female reproductive system—uterine cancer	0.000392	0.00464	CbGeAlD
Regorafenib—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.00039	0.00509	CcSEcCtD
Regorafenib—Mucosal inflammation—Doxorubicin—uterine cancer	0.00039	0.00509	CcSEcCtD
Regorafenib—KDR—endometrium—uterine cancer	0.000387	0.00458	CbGeAlD
Regorafenib—Erythema multiforme—Progesterone—uterine cancer	0.000386	0.00504	CcSEcCtD
Regorafenib—Polyp—Epirubicin—uterine cancer	0.000383	0.005	CcSEcCtD
Regorafenib—KIT—epithelium—uterine cancer	0.000382	0.00452	CbGeAlD
Regorafenib—Cardiac disorder—Progesterone—uterine cancer	0.000379	0.00495	CcSEcCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000379	0.173	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000379	0.173	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000379	0.173	CbGdCrCtD
Regorafenib—FLT1—female reproductive system—uterine cancer	0.000379	0.00448	CbGeAlD
Regorafenib—KIT—uterine cervix—uterine cancer	0.000379	0.00448	CbGeAlD
Regorafenib—RAF1—female reproductive system—uterine cancer	0.000377	0.00446	CbGeAlD
Regorafenib—Aspartate aminotransferase increased—Dactinomycin—uterine cancer	0.000376	0.0049	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.000376	0.0049	CcSEcCtD
Regorafenib—KDR—mammalian vulva—uterine cancer	0.000374	0.00443	CbGeAlD
Regorafenib—PDGFRB—epithelium—uterine cancer	0.000373	0.00442	CbGeAlD
Regorafenib—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.000372	0.00485	CcSEcCtD
Regorafenib—FGFR2—female gonad—uterine cancer	0.000372	0.0044	CbGeAlD
Regorafenib—Hypophosphataemia—Doxorubicin—uterine cancer	0.000371	0.00485	CcSEcCtD
Regorafenib—Angiopathy—Progesterone—uterine cancer	0.000371	0.00484	CcSEcCtD
Regorafenib—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00037	0.00483	CcSEcCtD
Regorafenib—PDGFRB—uterine cervix—uterine cancer	0.00037	0.00438	CbGeAlD
Regorafenib—KIT—smooth muscle tissue—uterine cancer	0.000368	0.00436	CbGeAlD
Regorafenib—Mediastinal disorder—Progesterone—uterine cancer	0.000368	0.0048	CcSEcCtD
Regorafenib—Hypomagnesaemia—Epirubicin—uterine cancer	0.000367	0.00479	CcSEcCtD
Regorafenib—EPHA2—female gonad—uterine cancer	0.000366	0.00433	CbGeAlD
Regorafenib—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.000366	0.00477	CcSEcCtD
Regorafenib—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000364	0.00475	CcSEcCtD
Regorafenib—EPHA2—vagina—uterine cancer	0.000363	0.0043	CbGeAlD
Regorafenib—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.000363	0.00473	CcSEcCtD
Regorafenib—KIT—decidua—uterine cancer	0.000361	0.00427	CbGeAlD
Regorafenib—Alopecia—Progesterone—uterine cancer	0.000361	0.00471	CcSEcCtD
Regorafenib—PDGFRB—smooth muscle tissue—uterine cancer	0.00036	0.00426	CbGeAlD
Regorafenib—Nail disorder—Epirubicin—uterine cancer	0.00036	0.00469	CcSEcCtD
Regorafenib—TEK—female gonad—uterine cancer	0.000357	0.00422	CbGeAlD
Regorafenib—KDR—uterus—uterine cancer	0.000356	0.00422	CbGeAlD
Regorafenib—Malnutrition—Progesterone—uterine cancer	0.000356	0.00464	CcSEcCtD
Regorafenib—PDGFRA—female reproductive system—uterine cancer	0.000355	0.0042	CbGeAlD
Regorafenib—Polyp—Doxorubicin—uterine cancer	0.000355	0.00463	CcSEcCtD
Regorafenib—KIT—renal system—uterine cancer	0.000354	0.00419	CbGeAlD
Regorafenib—PDGFRB—decidua—uterine cancer	0.000353	0.00417	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000351	0.16	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000351	0.16	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000351	0.16	CbGdCrCtD
Regorafenib—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00035	0.00457	CcSEcCtD
Regorafenib—Cyst—Epirubicin—uterine cancer	0.000349	0.00455	CcSEcCtD
Regorafenib—PDGFRB—renal system—uterine cancer	0.000346	0.0041	CbGeAlD
Regorafenib—FLT1—female gonad—uterine cancer	0.000345	0.00408	CbGeAlD
Regorafenib—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000344	0.00448	CcSEcCtD
Regorafenib—RAF1—female gonad—uterine cancer	0.000343	0.00406	CbGeAlD
Regorafenib—FLT1—vagina—uterine cancer	0.000343	0.00406	CbGeAlD
Regorafenib—KIT—endometrium—uterine cancer	0.000343	0.00406	CbGeAlD
Regorafenib—RAF1—vagina—uterine cancer	0.000341	0.00403	CbGeAlD
Regorafenib—Hypomagnesaemia—Doxorubicin—uterine cancer	0.00034	0.00443	CcSEcCtD
Regorafenib—Neutropenia—Dactinomycin—uterine cancer	0.000337	0.0044	CcSEcCtD
Regorafenib—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.000336	0.00438	CcSEcCtD
Regorafenib—PDGFRB—endometrium—uterine cancer	0.000335	0.00396	CbGeAlD
Regorafenib—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000334	0.00435	CcSEcCtD
Regorafenib—Tremor—Progesterone—uterine cancer	0.000333	0.00435	CcSEcCtD
Regorafenib—Nail disorder—Doxorubicin—uterine cancer	0.000333	0.00434	CcSEcCtD
Regorafenib—KIT—mammalian vulva—uterine cancer	0.000331	0.00392	CbGeAlD
Regorafenib—BRAF—lymph node—uterine cancer	0.000331	0.00391	CbGeAlD
Regorafenib—ABL1—uterine cervix—uterine cancer	0.00033	0.0039	CbGeAlD
Regorafenib—Anaemia—Progesterone—uterine cancer	0.000329	0.00429	CcSEcCtD
Regorafenib—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.000327	0.00427	CcSEcCtD
Regorafenib—PDGFRB—mammalian vulva—uterine cancer	0.000324	0.00383	CbGeAlD
Regorafenib—PDGFRA—female gonad—uterine cancer	0.000323	0.00382	CbGeAlD
Regorafenib—Cyst—Doxorubicin—uterine cancer	0.000323	0.00421	CcSEcCtD
Regorafenib—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000322	0.0042	CcSEcCtD
Regorafenib—PDGFRA—vagina—uterine cancer	0.000321	0.0038	CbGeAlD
Regorafenib—ABL1—smooth muscle tissue—uterine cancer	0.000321	0.00379	CbGeAlD
Regorafenib—KDR—female reproductive system—uterine cancer	0.00032	0.00379	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.000319	0.00416	CcSEcCtD
Regorafenib—EPHX2—lymph node—uterine cancer	0.000316	0.00374	CbGeAlD
Regorafenib—KIT—uterus—uterine cancer	0.000316	0.00374	CbGeAlD
Regorafenib—ABL1—decidua—uterine cancer	0.000314	0.00372	CbGeAlD
Regorafenib—Stomatitis—Dactinomycin—uterine cancer	0.000314	0.00409	CcSEcCtD
Regorafenib—ABL1—renal system—uterine cancer	0.000309	0.00365	CbGeAlD
Regorafenib—PDGFRB—uterus—uterine cancer	0.000308	0.00365	CbGeAlD
Regorafenib—Hypertension—Progesterone—uterine cancer	0.000307	0.00401	CcSEcCtD
Regorafenib—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000302	0.00394	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000301	0.00392	CcSEcCtD
Regorafenib—ABL1—endometrium—uterine cancer	0.000298	0.00353	CbGeAlD
Regorafenib—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.000298	0.00389	CcSEcCtD
Regorafenib—Dry mouth—Progesterone—uterine cancer	0.000296	0.00386	CcSEcCtD
Regorafenib—KDR—female gonad—uterine cancer	0.000291	0.00345	CbGeAlD
Regorafenib—KDR—vagina—uterine cancer	0.00029	0.00343	CbGeAlD
Regorafenib—ABL1—mammalian vulva—uterine cancer	0.000289	0.00341	CbGeAlD
Regorafenib—Infection—Progesterone—uterine cancer	0.000288	0.00376	CcSEcCtD
Regorafenib—FLT4—lymph node—uterine cancer	0.000285	0.00337	CbGeAlD
Regorafenib—Nervous system disorder—Progesterone—uterine cancer	0.000285	0.00371	CcSEcCtD
Regorafenib—KIT—female reproductive system—uterine cancer	0.000284	0.00336	CbGeAlD
Regorafenib—Dysphonia—Epirubicin—uterine cancer	0.000284	0.0037	CcSEcCtD
Regorafenib—Skin disorder—Progesterone—uterine cancer	0.000282	0.00368	CcSEcCtD
Regorafenib—FGFR1—lymph node—uterine cancer	0.000281	0.00333	CbGeAlD
Regorafenib—PDGFRB—female reproductive system—uterine cancer	0.000277	0.00328	CbGeAlD
Regorafenib—Liver injury—Epirubicin—uterine cancer	0.000277	0.00362	CcSEcCtD
Regorafenib—ABL1—uterus—uterine cancer	0.000275	0.00325	CbGeAlD
Regorafenib—Erythema multiforme—Dactinomycin—uterine cancer	0.000273	0.00356	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.00355	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000272	0.00355	CcSEcCtD
Regorafenib—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000268	0.0035	CcSEcCtD
Regorafenib—ABCG2—myometrium—uterine cancer	0.000267	0.00316	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000266	0.00348	CcSEcCtD
Regorafenib—Dysphonia—Doxorubicin—uterine cancer	0.000262	0.00342	CcSEcCtD
Regorafenib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00341	CcSEcCtD
Regorafenib—KIT—female gonad—uterine cancer	0.000258	0.00306	CbGeAlD
Regorafenib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000258	0.00336	CcSEcCtD
Regorafenib—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.00336	CcSEcCtD
Regorafenib—KIT—vagina—uterine cancer	0.000257	0.00304	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Epirubicin—uterine cancer	0.000257	0.00335	CcSEcCtD
Regorafenib—Liver injury—Doxorubicin—uterine cancer	0.000256	0.00335	CcSEcCtD
Regorafenib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000255	0.00333	CcSEcCtD
Regorafenib—Alopecia—Dactinomycin—uterine cancer	0.000255	0.00333	CcSEcCtD
Regorafenib—Hypocalcaemia—Epirubicin—uterine cancer	0.000255	0.00332	CcSEcCtD
Regorafenib—PDGFRB—female gonad—uterine cancer	0.000252	0.00299	CbGeAlD
Regorafenib—Decreased appetite—Progesterone—uterine cancer	0.000252	0.00329	CcSEcCtD
Regorafenib—RET—lymph node—uterine cancer	0.000252	0.00298	CbGeAlD
Regorafenib—Hyperuricaemia—Epirubicin—uterine cancer	0.000251	0.00328	CcSEcCtD
Regorafenib—PDGFRB—vagina—uterine cancer	0.000251	0.00297	CbGeAlD
Regorafenib—Gastrointestinal disorder—Progesterone—uterine cancer	0.000251	0.00327	CcSEcCtD
Regorafenib—Fatigue—Progesterone—uterine cancer	0.00025	0.00326	CcSEcCtD
Regorafenib—Pain—Progesterone—uterine cancer	0.000248	0.00324	CcSEcCtD
Regorafenib—ABL1—female reproductive system—uterine cancer	0.000247	0.00292	CbGeAlD
Regorafenib—Neutropenia—Etoposide—uterine cancer	0.000244	0.00319	CcSEcCtD
Regorafenib—Blood uric acid increased—Epirubicin—uterine cancer	0.000238	0.0031	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.000237	0.0031	CcSEcCtD
Regorafenib—Gastrointestinal pain—Progesterone—uterine cancer	0.000237	0.0031	CcSEcCtD
Regorafenib—Hypocalcaemia—Doxorubicin—uterine cancer	0.000236	0.00308	CcSEcCtD
Regorafenib—EPHA2—lymph node—uterine cancer	0.000235	0.00278	CbGeAlD
Regorafenib—Infestation—Etoposide—uterine cancer	0.000233	0.00304	CcSEcCtD
Regorafenib—Infestation NOS—Etoposide—uterine cancer	0.000233	0.00304	CcSEcCtD
Regorafenib—Hyperuricaemia—Doxorubicin—uterine cancer	0.000233	0.00304	CcSEcCtD
Regorafenib—Anaemia—Dactinomycin—uterine cancer	0.000232	0.00303	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000231	0.00301	CcSEcCtD
Regorafenib—Acute coronary syndrome—Etoposide—uterine cancer	0.000229	0.00299	CcSEcCtD
Regorafenib—Body temperature increased—Progesterone—uterine cancer	0.000229	0.00299	CcSEcCtD
Regorafenib—Abdominal pain—Progesterone—uterine cancer	0.000229	0.00299	CcSEcCtD
Regorafenib—TEK—lymph node—uterine cancer	0.000229	0.00271	CbGeAlD
Regorafenib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000229	0.00298	CcSEcCtD
Regorafenib—Myocardial infarction—Etoposide—uterine cancer	0.000228	0.00298	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000227	0.00296	CcSEcCtD
Regorafenib—Stomatitis—Etoposide—uterine cancer	0.000227	0.00296	CcSEcCtD
Regorafenib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000227	0.00296	CcSEcCtD
Regorafenib—Leukopenia—Dactinomycin—uterine cancer	0.000225	0.00294	CcSEcCtD
Regorafenib—ABL1—female gonad—uterine cancer	0.000225	0.00266	CbGeAlD
Regorafenib—ABL1—vagina—uterine cancer	0.000224	0.00264	CbGeAlD
Regorafenib—FLT1—lymph node—uterine cancer	0.000222	0.00262	CbGeAlD
Regorafenib—RAF1—lymph node—uterine cancer	0.00022	0.00261	CbGeAlD
Regorafenib—Hepatobiliary disease—Etoposide—uterine cancer	0.00022	0.00287	CcSEcCtD
Regorafenib—Blood uric acid increased—Doxorubicin—uterine cancer	0.00022	0.00287	CcSEcCtD
Regorafenib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000215	0.00281	CcSEcCtD
Regorafenib—Neoplasm—Epirubicin—uterine cancer	0.000211	0.00275	CcSEcCtD
Regorafenib—Asthenia—Progesterone—uterine cancer	0.000208	0.00272	CcSEcCtD
Regorafenib—ABCG2—uterine cervix—uterine cancer	0.000208	0.00246	CbGeAlD
Regorafenib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00271	CcSEcCtD
Regorafenib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00271	CcSEcCtD
Regorafenib—PDGFRA—lymph node—uterine cancer	0.000208	0.00246	CbGeAlD
Regorafenib—Urinary tract disorder—Etoposide—uterine cancer	0.000206	0.00269	CcSEcCtD
Regorafenib—Urethral disorder—Etoposide—uterine cancer	0.000205	0.00267	CcSEcCtD
Regorafenib—Infection—Dactinomycin—uterine cancer	0.000204	0.00266	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000201	0.00262	CcSEcCtD
Regorafenib—CYP2C8—renal system—uterine cancer	0.0002	0.00237	CbGeAlD
Regorafenib—Diarrhoea—Progesterone—uterine cancer	0.000199	0.00259	CcSEcCtD
Regorafenib—ABCG2—decidua—uterine cancer	0.000198	0.00234	CbGeAlD
Regorafenib—Erythema multiforme—Etoposide—uterine cancer	0.000198	0.00258	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—uterine cancer	0.000195	0.00255	CcSEcCtD
Regorafenib—Cardiac disorder—Etoposide—uterine cancer	0.000194	0.00253	CcSEcCtD
Regorafenib—CYP2C8—endometrium—uterine cancer	0.000193	0.00229	CbGeAlD
Regorafenib—Angiopathy—Etoposide—uterine cancer	0.00019	0.00247	CcSEcCtD
Regorafenib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000189	0.00246	CcSEcCtD
Regorafenib—Mediastinal disorder—Etoposide—uterine cancer	0.000188	0.00246	CcSEcCtD
Regorafenib—ABCG2—endometrium—uterine cancer	0.000188	0.00223	CbGeAlD
Regorafenib—KDR—lymph node—uterine cancer	0.000187	0.00222	CbGeAlD
Regorafenib—Alopecia—Etoposide—uterine cancer	0.000185	0.00241	CcSEcCtD
Regorafenib—Vomiting—Progesterone—uterine cancer	0.000185	0.00241	CcSEcCtD
Regorafenib—Rash—Progesterone—uterine cancer	0.000183	0.00239	CcSEcCtD
Regorafenib—Dermatitis—Progesterone—uterine cancer	0.000183	0.00239	CcSEcCtD
Regorafenib—ABCG2—mammalian vulva—uterine cancer	0.000182	0.00215	CbGeAlD
Regorafenib—Headache—Progesterone—uterine cancer	0.000182	0.00237	CcSEcCtD
Regorafenib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00018	0.00235	CcSEcCtD
Regorafenib—CYP2B6—renal system—uterine cancer	0.00018	0.00212	CbGeAlD
Regorafenib—Decreased appetite—Dactinomycin—uterine cancer	0.000178	0.00233	CcSEcCtD
Regorafenib—Fatigue—Dactinomycin—uterine cancer	0.000177	0.00231	CcSEcCtD
Regorafenib—Pain—Dactinomycin—uterine cancer	0.000175	0.00229	CcSEcCtD
Regorafenib—ABCG2—uterus—uterine cancer	0.000173	0.00205	CbGeAlD
Regorafenib—Nausea—Progesterone—uterine cancer	0.000172	0.00225	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—uterine cancer	0.00017	0.00222	CcSEcCtD
Regorafenib—Anaemia—Etoposide—uterine cancer	0.000168	0.00219	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000168	0.00219	CcSEcCtD
Regorafenib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000167	0.00218	CcSEcCtD
Regorafenib—CYP2C19—vagina—uterine cancer	0.000166	0.00197	CbGeAlD
Regorafenib—KIT—lymph node—uterine cancer	0.000166	0.00197	CbGeAlD
Regorafenib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000166	0.00216	CcSEcCtD
Regorafenib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000166	0.00216	CcSEcCtD
Regorafenib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000165	0.00215	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—uterine cancer	0.000163	0.00212	CcSEcCtD
Regorafenib—PDGFRB—lymph node—uterine cancer	0.000162	0.00192	CbGeAlD
Regorafenib—Body temperature increased—Dactinomycin—uterine cancer	0.000162	0.00212	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—uterine cancer	0.000162	0.00212	CcSEcCtD
Regorafenib—CYP2C8—female reproductive system—uterine cancer	0.00016	0.0019	CbGeAlD
Regorafenib—Hyponatraemia—Doxorubicin—uterine cancer	0.000157	0.00205	CcSEcCtD
Regorafenib—Hypertension—Etoposide—uterine cancer	0.000157	0.00205	CcSEcCtD
Regorafenib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000156	0.00204	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—uterine cancer	0.000155	0.00202	CcSEcCtD
Regorafenib—Hypokalaemia—Epirubicin—uterine cancer	0.000154	0.00201	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000154	0.00201	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000152	0.00199	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000152	0.00199	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000149	0.00195	CcSEcCtD
Regorafenib—Infection—Etoposide—uterine cancer	0.000147	0.00192	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—uterine cancer	0.000147	0.00192	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—uterine cancer	0.000145	0.0019	CcSEcCtD
Regorafenib—CYP2C8—vagina—uterine cancer	0.000145	0.00172	CbGeAlD
Regorafenib—ABL1—lymph node—uterine cancer	0.000145	0.00171	CbGeAlD
Regorafenib—Skin disorder—Etoposide—uterine cancer	0.000144	0.00188	CcSEcCtD
Regorafenib—CYP2B6—female reproductive system—uterine cancer	0.000144	0.0017	CbGeAlD
Regorafenib—Dry skin—Doxorubicin—uterine cancer	0.000144	0.00187	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—uterine cancer	0.000143	0.00186	CcSEcCtD
Regorafenib—CYP2C9—female reproductive system—uterine cancer	0.000142	0.00168	CbGeAlD
Regorafenib—ABCG2—female gonad—uterine cancer	0.000142	0.00168	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000141	0.00184	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000141	0.00184	CcSEcCtD
Regorafenib—ABCG2—vagina—uterine cancer	0.000141	0.00167	CbGeAlD
Regorafenib—Diarrhoea—Dactinomycin—uterine cancer	0.00014	0.00183	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000138	0.0018	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—uterine cancer	0.000137	0.00179	CcSEcCtD
Regorafenib—CYP3A4—renal system—uterine cancer	0.000136	0.0016	CbGeAlD
Regorafenib—Weight decreased—Epirubicin—uterine cancer	0.000132	0.00173	CcSEcCtD
Regorafenib—ABCB1—myometrium—uterine cancer	0.000132	0.00156	CbGeAlD
Regorafenib—Infestation—Epirubicin—uterine cancer	0.00013	0.0017	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—uterine cancer	0.00013	0.0017	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—uterine cancer	0.00013	0.0017	CcSEcCtD
Regorafenib—CYP2B6—vagina—uterine cancer	0.00013	0.00154	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000129	0.00169	CcSEcCtD
Regorafenib—Rash—Dactinomycin—uterine cancer	0.000129	0.00169	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—uterine cancer	0.000129	0.00168	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000128	0.00167	CcSEcCtD
Regorafenib—Fatigue—Etoposide—uterine cancer	0.000128	0.00167	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—uterine cancer	0.000127	0.00166	CcSEcCtD
Regorafenib—Pain—Etoposide—uterine cancer	0.000127	0.00166	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—uterine cancer	0.000127	0.00165	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000123	0.00161	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—uterine cancer	0.000123	0.0016	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—uterine cancer	0.000122	0.00159	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—uterine cancer	0.000121	0.00158	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—uterine cancer	0.000121	0.00158	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—uterine cancer	0.000121	0.00158	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00012	0.00156	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—uterine cancer	0.000118	0.00154	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—uterine cancer	0.000118	0.00154	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—uterine cancer	0.000117	0.00153	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—uterine cancer	0.000117	0.00153	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—uterine cancer	0.000117	0.00153	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—uterine cancer	0.000116	0.00151	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—uterine cancer	0.000115	0.0015	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—uterine cancer	0.000115	0.0015	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000114	0.00149	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—uterine cancer	0.000111	0.00145	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—uterine cancer	0.000109	0.00142	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—uterine cancer	0.000109	0.00142	CcSEcCtD
Regorafenib—CYP3A4—female reproductive system—uterine cancer	0.000109	0.00128	CbGeAlD
Regorafenib—Haemorrhage—Doxorubicin—uterine cancer	0.000108	0.00141	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000107	0.0014	CcSEcCtD
Regorafenib—Asthenia—Etoposide—uterine cancer	0.000107	0.00139	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000107	0.00139	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—uterine cancer	0.000106	0.00139	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—uterine cancer	0.000106	0.00139	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—uterine cancer	0.000106	0.00138	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—uterine cancer	0.000104	0.00135	CcSEcCtD
Regorafenib—ABCB1—epithelium—uterine cancer	0.000103	0.00122	CbGeAlD
Regorafenib—ABCB1—uterine cervix—uterine cancer	0.000103	0.00121	CbGeAlD
Regorafenib—Erythema multiforme—Doxorubicin—uterine cancer	0.000102	0.00134	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—uterine cancer	0.000102	0.00133	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—uterine cancer	0.000102	0.00133	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—uterine cancer	0.000101	0.00131	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—uterine cancer	9.83e-05	0.00128	CcSEcCtD
Regorafenib—ABCB1—decidua—uterine cancer	9.77e-05	0.00116	CbGeAlD
Regorafenib—Mediastinal disorder—Doxorubicin—uterine cancer	9.77e-05	0.00127	CcSEcCtD
Regorafenib—ABCB1—renal system—uterine cancer	9.6e-05	0.00114	CbGeAlD
Regorafenib—Alopecia—Doxorubicin—uterine cancer	9.58e-05	0.00125	CcSEcCtD
Regorafenib—Vomiting—Etoposide—uterine cancer	9.44e-05	0.00123	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—uterine cancer	9.43e-05	0.00123	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—uterine cancer	9.42e-05	0.00123	CcSEcCtD
Regorafenib—Rash—Etoposide—uterine cancer	9.36e-05	0.00122	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—uterine cancer	9.35e-05	0.00122	CcSEcCtD
Regorafenib—Headache—Etoposide—uterine cancer	9.3e-05	0.00121	CcSEcCtD
Regorafenib—ABCB1—endometrium—uterine cancer	9.28e-05	0.0011	CbGeAlD
Regorafenib—Leukopenia—Epirubicin—uterine cancer	9.13e-05	0.00119	CcSEcCtD
Regorafenib—ABCG2—lymph node—uterine cancer	9.12e-05	0.00108	CbGeAlD
Regorafenib—ABCB1—mammalian vulva—uterine cancer	8.97e-05	0.00106	CbGeAlD
Regorafenib—Nausea—Etoposide—uterine cancer	8.82e-05	0.00115	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—uterine cancer	8.8e-05	0.00115	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—uterine cancer	8.72e-05	0.00114	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	8.62e-05	0.00112	CcSEcCtD
Regorafenib—ABCB1—uterus—uterine cancer	8.55e-05	0.00101	CbGeAlD
Regorafenib—Dry mouth—Epirubicin—uterine cancer	8.49e-05	0.00111	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—uterine cancer	8.45e-05	0.0011	CcSEcCtD
Regorafenib—Infection—Epirubicin—uterine cancer	8.27e-05	0.00108	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—uterine cancer	8.16e-05	0.00106	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—uterine cancer	8.15e-05	0.00106	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—uterine cancer	8.15e-05	0.00106	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—uterine cancer	8.08e-05	0.00105	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	7.98e-05	0.00104	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—uterine cancer	7.86e-05	0.00102	CcSEcCtD
Regorafenib—ABCB1—female reproductive system—uterine cancer	7.68e-05	0.000909	CbGeAlD
Regorafenib—Infection—Doxorubicin—uterine cancer	7.65e-05	0.000998	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—uterine cancer	7.55e-05	0.000985	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—uterine cancer	7.54e-05	0.000984	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—uterine cancer	7.48e-05	0.000976	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—uterine cancer	7.23e-05	0.000944	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—uterine cancer	7.18e-05	0.000937	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—uterine cancer	7.17e-05	0.000936	CcSEcCtD
Regorafenib—Pain—Epirubicin—uterine cancer	7.12e-05	0.000929	CcSEcCtD
Regorafenib—ABCB1—female gonad—uterine cancer	6.99e-05	0.000827	CbGeAlD
Regorafenib—ABCB1—vagina—uterine cancer	6.95e-05	0.000822	CbGeAlD
Regorafenib—Gastrointestinal pain—Epirubicin—uterine cancer	6.81e-05	0.000888	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—uterine cancer	6.69e-05	0.000873	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—uterine cancer	6.65e-05	0.000867	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—uterine cancer	6.64e-05	0.000866	CcSEcCtD
Regorafenib—Pain—Doxorubicin—uterine cancer	6.58e-05	0.000859	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—uterine cancer	6.58e-05	0.000858	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—uterine cancer	6.58e-05	0.000858	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—uterine cancer	6.3e-05	0.000822	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—uterine cancer	6.09e-05	0.000794	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—uterine cancer	6.09e-05	0.000794	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—uterine cancer	5.97e-05	0.000779	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—uterine cancer	5.69e-05	0.000743	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—uterine cancer	5.52e-05	0.000721	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—uterine cancer	5.29e-05	0.00069	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—uterine cancer	5.27e-05	0.000687	CcSEcCtD
Regorafenib—Rash—Epirubicin—uterine cancer	5.25e-05	0.000685	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—uterine cancer	5.24e-05	0.000684	CcSEcCtD
Regorafenib—Headache—Epirubicin—uterine cancer	5.21e-05	0.00068	CcSEcCtD
Regorafenib—Nausea—Epirubicin—uterine cancer	4.94e-05	0.000645	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—uterine cancer	4.9e-05	0.000639	CcSEcCtD
Regorafenib—Rash—Doxorubicin—uterine cancer	4.86e-05	0.000633	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—uterine cancer	4.85e-05	0.000633	CcSEcCtD
Regorafenib—Headache—Doxorubicin—uterine cancer	4.82e-05	0.000629	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—uterine cancer	4.57e-05	0.000597	CcSEcCtD
Regorafenib—ABCB1—lymph node—uterine cancer	4.5e-05	0.000532	CbGeAlD
Regorafenib—PDGFRB—Immune System—NRAS—uterine cancer	3.19e-06	2.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PTEN—uterine cancer	3.19e-06	2.58e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—ERBB2—uterine cancer	3.18e-06	2.58e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—uterine cancer	3.16e-06	2.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—AKT1—uterine cancer	3.16e-06	2.56e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EP300—uterine cancer	3.15e-06	2.55e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NRAS—uterine cancer	3.12e-06	2.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—NRAS—uterine cancer	3.11e-06	2.52e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NRAS—uterine cancer	3.11e-06	2.52e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CTNNB1—uterine cancer	3.09e-06	2.5e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCL8—uterine cancer	3.07e-06	2.49e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CTNNB1—uterine cancer	3.06e-06	2.48e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KRAS—uterine cancer	3.06e-06	2.48e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POLD1—uterine cancer	3.06e-06	2.47e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KRAS—uterine cancer	3.05e-06	2.47e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EP300—uterine cancer	3.04e-06	2.46e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HRAS—uterine cancer	3.04e-06	2.46e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—AKT1—uterine cancer	3.03e-06	2.45e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—AKT1—uterine cancer	3.03e-06	2.45e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KRAS—uterine cancer	3.03e-06	2.45e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CTNNB1—uterine cancer	3.02e-06	2.45e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ERBB2—uterine cancer	3.02e-06	2.44e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCL8—uterine cancer	3.02e-06	2.44e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—PIK3CA—uterine cancer	3.01e-06	2.44e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ERBB2—uterine cancer	3.01e-06	2.44e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PTEN—uterine cancer	3.01e-06	2.44e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PIK3CA—uterine cancer	3e-06	2.43e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CDKN1B—uterine cancer	3e-06	2.43e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3e-06	2.43e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PTEN—uterine cancer	2.98e-06	2.41e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—KRAS—uterine cancer	2.98e-06	2.41e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—PIK3CA—uterine cancer	2.96e-06	2.4e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NRAS—uterine cancer	2.95e-06	2.39e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CDKN1B—uterine cancer	2.95e-06	2.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTEN—uterine cancer	2.95e-06	2.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL2—uterine cancer	2.9e-06	2.35e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EP300—uterine cancer	2.87e-06	2.32e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCL8—uterine cancer	2.86e-06	2.32e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.86e-06	2.31e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.86e-06	2.31e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCL8—uterine cancer	2.86e-06	2.31e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—STK11—uterine cancer	2.85e-06	2.31e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP19A1—uterine cancer	2.85e-06	2.31e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NRAS—uterine cancer	2.85e-06	2.3e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KRAS—uterine cancer	2.84e-06	2.3e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EP300—uterine cancer	2.84e-06	2.3e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—MTHFR—uterine cancer	2.83e-06	2.3e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CTNNB1—uterine cancer	2.83e-06	2.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KRAS—uterine cancer	2.82e-06	2.29e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KRAS—uterine cancer	2.82e-06	2.28e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—PIK3CA—uterine cancer	2.81e-06	2.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EP300—uterine cancer	2.81e-06	2.27e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—PIK3CA—uterine cancer	2.8e-06	2.27e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CDKN1B—uterine cancer	2.8e-06	2.26e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CDKN1B—uterine cancer	2.79e-06	2.26e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HRAS—uterine cancer	2.79e-06	2.26e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CTNNB1—uterine cancer	2.78e-06	2.25e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PIK3CA—uterine cancer	2.78e-06	2.25e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—STK11—uterine cancer	2.78e-06	2.25e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP19A1—uterine cancer	2.78e-06	2.25e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—HRAS—uterine cancer	2.78e-06	2.25e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PTEN—uterine cancer	2.76e-06	2.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KRAS—uterine cancer	2.75e-06	2.22e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—HRAS—uterine cancer	2.74e-06	2.22e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PIK3CA—uterine cancer	2.73e-06	2.21e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—uterine cancer	2.72e-06	2.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ERBB2—uterine cancer	2.71e-06	2.2e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PTEN—uterine cancer	2.71e-06	2.2e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—uterine cancer	2.69e-06	2.18e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KRAS—uterine cancer	2.69e-06	2.18e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NRAS—uterine cancer	2.68e-06	2.17e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—AKT1—uterine cancer	2.68e-06	2.17e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—KRAS—uterine cancer	2.68e-06	2.17e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KRAS—uterine cancer	2.68e-06	2.17e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.68e-06	2.17e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—AKT1—uterine cancer	2.67e-06	2.16e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NRAS—uterine cancer	2.66e-06	2.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CTNNB1—uterine cancer	2.64e-06	2.14e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	2.64e-06	2.13e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EP300—uterine cancer	2.63e-06	2.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NRAS—uterine cancer	2.63e-06	2.13e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PIK3CA—uterine cancer	2.61e-06	2.12e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—uterine cancer	2.6e-06	2.1e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—STK11—uterine cancer	2.6e-06	2.1e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP19A1—uterine cancer	2.6e-06	2.1e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PIK3CA—uterine cancer	2.59e-06	2.1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—uterine cancer	2.59e-06	2.1e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EP300—uterine cancer	2.59e-06	2.09e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PIK3CA—uterine cancer	2.59e-06	2.09e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTEN—uterine cancer	2.58e-06	2.08e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—uterine cancer	2.58e-06	2.08e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	2.57e-06	2.08e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	2.57e-06	2.08e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.55e-06	2.07e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—RRM2—uterine cancer	2.55e-06	2.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—uterine cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTEN—uterine cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTEN—uterine cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—uterine cancer	2.53e-06	2.05e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—uterine cancer	2.53e-06	2.05e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—PIK3CA—uterine cancer	2.52e-06	2.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	2.51e-06	2.03e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—uterine cancer	2.5e-06	2.02e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—DCN—uterine cancer	2.47e-06	2e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PIK3CA—uterine cancer	2.47e-06	2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—uterine cancer	2.46e-06	2e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PIK3CA—uterine cancer	2.46e-06	1.99e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—uterine cancer	2.46e-06	1.99e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PIK3CA—uterine cancer	2.46e-06	1.99e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EP300—uterine cancer	2.46e-06	1.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—uterine cancer	2.45e-06	1.99e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—uterine cancer	2.45e-06	1.98e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EP300—uterine cancer	2.45e-06	1.98e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—uterine cancer	2.45e-06	1.98e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.44e-06	1.98e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—uterine cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—uterine cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—uterine cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—EP300—uterine cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—EP300—uterine cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—uterine cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—uterine cancer	2.4e-06	1.94e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—uterine cancer	2.4e-06	1.94e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—uterine cancer	2.39e-06	1.94e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—uterine cancer	2.39e-06	1.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	2.37e-06	1.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—uterine cancer	2.34e-06	1.89e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—uterine cancer	2.33e-06	1.89e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.33e-06	1.89e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.33e-06	1.88e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—uterine cancer	2.33e-06	1.88e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	2.32e-06	1.88e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	2.31e-06	1.87e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—uterine cancer	2.31e-06	1.87e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—uterine cancer	2.3e-06	1.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—uterine cancer	2.3e-06	1.86e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—uterine cancer	2.29e-06	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	2.29e-06	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—uterine cancer	2.29e-06	1.85e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—uterine cancer	2.29e-06	1.85e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—uterine cancer	2.28e-06	1.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—uterine cancer	2.28e-06	1.84e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—uterine cancer	2.28e-06	1.84e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—uterine cancer	2.27e-06	1.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—uterine cancer	2.26e-06	1.83e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—uterine cancer	2.25e-06	1.82e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—uterine cancer	2.24e-06	1.81e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—uterine cancer	2.23e-06	1.81e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EP300—uterine cancer	2.21e-06	1.79e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.2e-06	1.78e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—uterine cancer	2.16e-06	1.75e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—uterine cancer	2.15e-06	1.74e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—uterine cancer	2.14e-06	1.73e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—uterine cancer	2.13e-06	1.73e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—uterine cancer	2.12e-06	1.72e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—uterine cancer	2.12e-06	1.72e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—uterine cancer	2.12e-06	1.72e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—uterine cancer	2.12e-06	1.71e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.11e-06	1.71e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—uterine cancer	2.11e-06	1.71e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—uterine cancer	2.1e-06	1.7e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—uterine cancer	2.09e-06	1.69e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	2.09e-06	1.69e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—uterine cancer	2.08e-06	1.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—uterine cancer	2.08e-06	1.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—uterine cancer	2.08e-06	1.68e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	2.06e-06	1.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—uterine cancer	2.06e-06	1.67e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—uterine cancer	2.06e-06	1.67e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—uterine cancer	2.05e-06	1.66e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—EP300—uterine cancer	2.05e-06	1.66e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—uterine cancer	2.03e-06	1.65e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—uterine cancer	2.02e-06	1.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—uterine cancer	2.01e-06	1.63e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—uterine cancer	2.01e-06	1.63e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—uterine cancer	1.98e-06	1.6e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	1.97e-06	1.6e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EP300—uterine cancer	1.97e-06	1.59e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—uterine cancer	1.96e-06	1.59e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—uterine cancer	1.95e-06	1.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—uterine cancer	1.95e-06	1.58e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—uterine cancer	1.95e-06	1.58e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—uterine cancer	1.92e-06	1.56e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—uterine cancer	1.91e-06	1.55e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—uterine cancer	1.9e-06	1.54e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.89e-06	1.53e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—uterine cancer	1.89e-06	1.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—uterine cancer	1.86e-06	1.51e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—uterine cancer	1.85e-06	1.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—uterine cancer	1.84e-06	1.49e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—uterine cancer	1.84e-06	1.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—uterine cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	1.81e-06	1.47e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—uterine cancer	1.8e-06	1.46e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—uterine cancer	1.79e-06	1.45e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—uterine cancer	1.79e-06	1.45e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	1.78e-06	1.44e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—uterine cancer	1.77e-06	1.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—uterine cancer	1.76e-06	1.42e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—uterine cancer	1.75e-06	1.42e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—uterine cancer	1.73e-06	1.4e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.72e-06	1.39e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—uterine cancer	1.72e-06	1.39e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—STK11—uterine cancer	1.71e-06	1.39e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.71e-06	1.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—uterine cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—uterine cancer	1.68e-06	1.36e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	1.68e-06	1.36e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	1.63e-06	1.32e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—uterine cancer	1.59e-06	1.29e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—uterine cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—uterine cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—uterine cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—uterine cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—uterine cancer	1.52e-06	1.23e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	1.51e-06	1.22e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—EP300—uterine cancer	1.5e-06	1.22e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—uterine cancer	1.48e-06	1.2e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	1.48e-06	1.2e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—uterine cancer	1.46e-06	1.18e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—uterine cancer	1.46e-06	1.18e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—uterine cancer	1.45e-06	1.18e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—uterine cancer	1.41e-06	1.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—uterine cancer	1.35e-06	1.09e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—uterine cancer	1.34e-06	1.08e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.33e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.29e-06	1.04e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—EP300—uterine cancer	1.27e-06	1.03e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—uterine cancer	1.24e-06	1e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—uterine cancer	1.19e-06	9.65e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—uterine cancer	1.19e-06	9.62e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—uterine cancer	1.16e-06	9.42e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—EP300—uterine cancer	1.14e-06	9.2e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—uterine cancer	1.11e-06	9.01e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—EP300—uterine cancer	1.11e-06	8.98e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—uterine cancer	1.09e-06	8.8e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—EP300—uterine cancer	1.04e-06	8.39e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—uterine cancer	9.42e-07	7.63e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—uterine cancer	9.09e-07	7.36e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—uterine cancer	8.41e-07	6.81e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—uterine cancer	8.21e-07	6.64e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—uterine cancer	7.69e-07	6.23e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—uterine cancer	7.67e-07	6.21e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—uterine cancer	7.17e-07	5.8e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—uterine cancer	6.87e-07	5.56e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—EP300—uterine cancer	6.83e-07	5.53e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—uterine cancer	6.7e-07	5.43e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—uterine cancer	6.26e-07	5.07e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.06e-07	4.09e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—uterine cancer	4.13e-07	3.34e-06	CbGpPWpGaD
